-
Exscientia, GSK Enter into Drug Discovery Collaboration
americanpharmaceuticalreview
July 04, 2017
Exscientia has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK).
-
Exscientia enters strategic drug discovery collaboration with GSK
cphi-online
July 04, 2017
Pre-clinical collaboration focused on up to 10 targets nominated by GSK.
-
GSK tests mepolizumab for nasal polyps
pharmatimes
June 30, 2017
GSK tests mepolizumab for nasal polyps
-
GSK wins $235mn patent infringement case against Teva
biospectrumasia
June 26, 2017
Earlier in 2014, GSK had sued Teva for filing an Abbreviated New Drug Application seeking to market carvedilol, a class of chemical compounds used to treat patients with high blood pressure and heart failure
-
GSK’s new pharma chief Miels to join in September
pharmaphorum
June 22, 2017
GlaxoSmithKline’s new head of pharmaceuticals, Luke Miels, will start work in September, after the company settled a contract dispute with UK rivals AstraZeneca.
-
AZ launches lawsuit against former executive for defecting to GSK
pharmafile
May 18, 2017
AstraZeneca has launched a lawsuit against one of its former executives after he jumped ship to join rival pharma giant GlaxoSmithKline.
-
US FDA issues CRL to Hikma’s generic version of GSK’s Advair Diskus
pharmaceutical-technology
May 16, 2017
Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and salmeterol inhalation powder).
-
GSK 'real world' drug test has second success in asthma
biospectrumasia
May 15, 2017
The study showed the drug, which is marketed as Relvar in Europe, was superior in controlling symptoms of asthma compared to usual care, based on a standardized questionnaire filled out by patients.
-
GSK ends Vaxem Hib production, costing Takeda a planned launch in Japan
fiercepharma
May 10, 2017
Takeda’s plan to launch a Haemophilus influenzae type B (Hib) vaccine in Japan has ended in smoke as manufacturer GlaxoSmithKline has terminated production of Vaxem Hib.
-
Immunocore and GSK identify second new ImmTAC for cancer treatment
pharmaceutical-technology
May 09, 2017
UK-based biotechnology firm Immunocore and GlaxoSmithKline (GSK) have identified a lead compound as part of their second discovery programme.